Esketamine Nasal Spray for Treatment-Resistant Bipolar II Depression: A Case Report
Psychiatry Investigation October 15, 2025 Hong-Ci Lin, Chia-Yu Chang, Ching-Huang Lin et al. 1 citation
This case report discusses a 62-year-old male with treatment-resistant bipolar II depression and hypertension. After poor responses to multiple treatments, an add-on esketamine nasal spray (ESK-NS) was introduced in October 2022. Improvement was seen, and the patient's depressive episode was nearly remitted during the maintenance phase. However, recurrence was noted when ESK-NS frequency was...